Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APVO442
- Development stage
- Preclinical
- Lead developer
- Aptevo Therapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
APVO442 is a preclinical, investigational bispecific antibody developed by Aptevo Therapeutics. Engineered using the ADAPTIR-FLEX platform, it is designed to treat prostate cancer by targeting Prostate-Specific Membrane Antigen (PSMA) on cancer cells and CD3 on T cells. This dual targeting aims to selectively activate T cells within the tumor microenvironment, leading to targeted immune responses and enhanced tumor cell killing, while minimizing systemic toxicity and cytokine release through its optimized binding affinities.
02
Targets
CD3 (T-cell surface glycoprotein CD3)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on APVO442.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APVO442.